Integrated Solutions: Combining Multiple Endpoints into a Single Study Delivers Greater Confidence

covance_knife“The whole is greater than the sum of its parts” is often quoted to inspire teamwork and synergy but it can also apply to drug development. Studies that assess endpoints in isolation have value and can achieve the desired outcome.  Yet, many times a more complicated picture emerges and assessing multiple endpoints in a combined study reveals a more holistic view.

Inspired by the 3Rs—reduction, refinement and replacement of animals used in safety testing—the possibility of integrating multiple endpoints into one study is shaping new best practices in early drug development. Integrated solutions can maximize the value of each study to provide a better understanding, reveal earlier decision points and produce greater confidence in clinical outcomes.

While the concept seems straightforward, it’s not only a combination of otherwise standalone studies. Integrated solutions require a unique blend of fit-for-purpose experimental strategies tailored to each unique drug development program and the relevant endpoints. Continue reading

The Growing “Need for Speed” in Food Pathogen Testing

102050_AB Still C1091It seems every few months there’s another announcement about a new rapid method to test for pathogens. These developments have food manufacturers talking, but why the growing need for speed when it comes to food pathogen testing? And how do you know which method is right for you?

Faster answers, minimizing impact

The benefits of rapid testing are most obvious when you consider the investigation of a food-borne illness outbreak caused by a pathogen such as Listeria monocytogenes, E.coli  O157:H7 or Salmonella. These methods allow investigators to quickly link case strains and screen more samples. They also can accelerate root cause investigations so manufacturers can get to a resolution more quickly. Continue reading

The CiPA Debate: What You Should Know

ecg-printoutH1Debate around best practices for safety pharmacology continued on December 11, 2014 as global regulators, drug developers and scientists from contract research organizations gathered in Silver Spring, MD for a workshop on the Comprehensive in vitro Proarrhythmia Assay (CiPA) and the clinical QT testing initiatives that stand to create a new paradigm in cardiac safety testing and drug development.

So, what led to the proposal for this sweeping change and why the debate? Continue reading

Market Access in Asia: What Role for Health Economics?

market-access-in-asiaThe pharmaceutical, medical device and diagnostics industries are very interested in the changing market access landscape in South and East Asia because of the vast commercial potential of this area. This region has a large proportion of the world’s population (~60%), a 2011 gross domestic product (GDP) growth that is almost triple the average of Europe and North America, and a huge opportunity for improvements in healthcare.

Market access requirements
Current market access requirements vary considerably among the countries in South and East Asia. Many of them – including China and India – do not have any formal comparative effectiveness or health economic criteria for national pricing and reimbursement submissions. Health economics generally plays a minor role in their decision-making. Continue reading

Increase Compound Efficacy with an Integrated Approach


Iteration is the key for earlier and better decisions
The great inventor Thomas Edison once said, “I have not failed. I’ve just found 10,000 ways that won’t work.” While he was not talking about compounds, he could have been. The likelihood of success for any given compound is less than one percent. Aggravating the situation are several other factors, including constant pressure on decreasing pricing, quickly diminishing point of return at the 20-year mark, and along the way, inherent risk and large investments.

Still, we persevere. But to be successful in today’s environment requires a different, non-linear approach. The status quo will not work. We recommend taking a holistic view of the drug development process and an integrated approach. Continue reading

Detecting and Quantifying Mycotoxins with LC-MS/MS

mycotoxinWith the availability of sensitive mass selective instruments, such as tandem mass spectrometers and high-resolution mass spectrometers, today’s food safety chemists have the ability to accurately analyze multiple classes of mytotoxins simultaneously with minimal sample preparation. Mycotoxins, which are low-molecular weight, chemically diverse toxins, are produced naturally by molds commonly found in grains and fruit and have been linked to a wide range of negative health effects.

Performing mycotoxin analysis has been a long-standing challenge for food safety chemists. Stringent requirements from governing bodies demand accurate limits of quantification at low ug/kg levels and test the limits of standard laboratory instruments and typical extraction and purification techniques. The task is further complicated when the simultaneous analysis of multiple classes of mytocoxins is desired. However, with the advent of liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) methods, food chemists are now able to analyze food products for accurate and reproducible quantification of very low levels of several mycotoxins at once.

Regulating Mycotoxins

Mycotoxins are secondary metabolites produced by various species of fungi under certain environmental conditions. These toxins display numerous adverse physiological responses in plants, animals and humans. For example, mycotoxins may act as carcinogens, teratogens, genotoxins, nephrotoxins, nerotoxins, hepatoxins and immunosuppressors in mammals. Mycotoxins have been implicated as causes of cancer and mutagenicity, as well as estrogenic, gastrointestinal, urogenital, vascular, kidney and nervous disorders.

Due to these detrimental health effects of mytotoxins, regulatory bodies have instituted action levels for various mycotoxins in foods and feed worldwide. For example, the EU has regulated the content of aflatoxins, fumonisins, selected trichothecenes, ochratoxin A, zearalenone and patulin in differing commodities. In the U.S., the FDA has regulated the level of aflatoxins, deoxynivalenol and patulin in foods and feed.

Advantages of LC-MS/MS for Mycotoxin Testing

Historically, individual mycotoxins or their classes have been analyzed with analyte/specific methods. Typical techniques of analysis have included HPLC with floresence or UV detection, GC with FID or EC detection and ELISA. Mass spectrometry has also been used for targeted analysis of individual or similar groups of mytotoxins. With the introduction of sensitive, fast scanning tandem mass spectrometers, multi-mycotoxin analysis for routine samples after non-targeted extractions is now feasible.

Overall, LC-MS/MS is a highly specific and extremely sensitive technique for testing food products with superior accuracy and higher throughput than traditional analytical methods. LC-MS/MS allows the potential monitoring of hundreds of contaminants in a single run, plus it requires less sample preparation due to its level of sensitivity. For mycotoxins specifically, LC-MS/MS is a powerful tool as it allows laboratories to confirm the presence and structure of multiple mycotoxins simultaneously, in less time, with greater accuracy. Food chemists can screen for, quantitate and identify several mycotoxins in a single run on a single system.

For more information on our mycotoxin testing capabilities, please visit

Multi-Criteria Decision Analysis in Health Technology Risk-Benefit Analysis: The Future?


Current trends in health technology assessment (HTA) indicate a shift away from the use of cost-effectiveness to value-related measures. A suite of analysis methods, collectively referred to as “risk-benefit analysis”, can be used to address these requirements. Of these, multi-criteria decision analysis (MCDA) is considered a leading candidate for practical application in HTA.

Limitations of cost-effectiveness analyses
The quality-adjusted life-year (QALY), frequently used in cost-effectiveness analyses and once the gold-standard outcome measure for economic evaluation in healthcare, is coming under heavier criticism than ever before. While appropriate in certain situations, the instruments used to generate QALYs have been shown to lack the required sensitivity to capture all benefits of interventions in some therapy areas, including hearing loss and schizophrenia. Continue reading

What to Look for When Recruiting Patient Arms for Phase I


A five-point checklist for early, positive studies

Now more than ever, there is increasing pressure to bring new drugs to market more efficiently. With so much at stake when introducing a drug into the human body for the first time, you need to consider safety and efficacy and an ability to make a decision whether and how to proceed at every turn. As a result, you want to improve the earlier stages of drug development to enhance the quality of compounds that progress to Phase III. The end goal? To increase the success rate of molecules in Phase III. Continue reading

Price Disparity: Will It Ever Truly Disappear?


Geographic price disparity between pharmaceutical products exists due to the variation in national economies and the unique ways that each country determines the price of pharmaceuticals. Price disparity still exists even in areas of “free trade” or in a single combined market of multiple countries, such as the European Union. This has led to parallel trade, where products are purchased in countries with lower prices and sold in those with higher prices. The fact that such disparities can develop seems contrary to the concept of a simple, free market, and it raises the question of whether price disparity will ever truly disappear.

The principle of free trade and tariff-free access to economic goods across borders is a founding principle of the EU and other regional trade agreements. Therefore, the continued existence of legal parallel trade combined with international referencing could lead to the end of price disparity, with prices converging to an average regional price. Continue reading

LC-MS/MS Emerges As New Method of Analysis for Vitamin B Testing

BVitaminsAnalytical test methods for vitamin testing in foods have been in existence for decades, including microbiological and high performance liquid chromatography (HPLC) methods. While these methods are still considered the “gold standards” for vitamin testing, a new method, liquid chromatography tandem mass spectrometry (LC-MS/MS), is emerging. LC-MS/MS can offer several advantages over the older methods, including greater sensitivity, precision, simplified sample prep, quantitative dynamic range, and most importantly multiplexing.

This new method is an important solution for our food manufacturer sponsors, as it provides you with faster and more reliable data, as well as potential cost savings if you need a full B-vitamin profile. Continue reading